NTRA Natera, Inc. Earnings per share growth rate in current year

Natera, Inc. (NTRA) is exposed to raw material supply chain disruption risks stemming from global conflicts. Business success relies on insurance coverage for tests and patent protection. Growth is driven by internal R&D and partnerships with oncology centers. The current level of the indicator is -5.10, which is detailed by the relative EPS YoY price action.
Comprehensive metric breakdowns and analytics for Natera, Inc. (NTRA)
- current quotes and average value forecast:
- market capitalization data:
- balance sheet equity data:
- debt and liquidity details:
- earnings and market ratios statistics:
NTRA - Net Income|Expected Net Income Natera, Inc.|NTRA - P/E Multiple|Market Cap to Projected Earnings natera.com|NTRA - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Natera|NTRA - Operating profit EBITDA|Net earnings per share for the last 12 months Natera|NTRA - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months natera.com|NTRA - Earnings per share growth in current year|Projected earnings per share growth rate for next year Natera, Inc.
- revenue and sales proceeds data:
Fundamental valuation:NTRA Natera Medical

This metric measures the annual trend of earnings per share, reflecting the efficiency of net income generation relative to total capital. By analyzing the annual EPS change, an investor assesses the ability of Natera, Inc. (NTRA) to monetize its patents and genetic data assets amidst fierce competition with laboratory behemoths, which confirms the resilience of its market advantage.